Sana Biotechnology Q3 2023 Earnings Report $1.68 -0.23 (-11.78%) (As of 05:45 PM ET) Earnings HistoryForecast Sana Biotechnology EPS ResultsActual EPS-$0.41Consensus EPS -$0.45Beat/MissBeat by +$0.04One Year Ago EPSN/ASana Biotechnology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASana Biotechnology Announcement DetailsQuarterQ3 2023Date11/8/2023TimeQ3 2023 Earnings ReleaseConference Call ResourcesPress ReleaseSANA Earnings HistoryPowered by U.S. Government: “this could save civilization.” (Ad)Experts indicate that ChatGPT alone consumes up to 17,000 times more electricity than the average U.S. household uses in a single day. And with companies like Google and Microsoft implementing AI into everything we do, that energy consumption is only going to exponentially increase. Thing is, outside of a small group of elite investors, nobody has connected the dots on how this military contractor could be the most important company in the AI boom.To get all the details, go here now. Sana Biotechnology Earnings HeadlinesSana Biotechnology (SANA) Receives a Buy from Morgan StanleyDecember 5, 2024 | markets.businessinsider.comSana: Major Inflection Point For SC291 In 2025 Targeting LupusDecember 4, 2024 | seekingalpha.comU.S. Government: “this could save civilization.”Experts indicate that ChatGPT alone consumes up to 17,000 times more electricity than the average U.S. household uses in a single day. And with companies like Google and Microsoft implementing AI into everything we do, that energy consumption is only going to exponentially increase. Thing is, outside of a small group of elite investors, nobody has connected the dots on how this military contractor could be the most important company in the AI boom.December 18, 2024 | Porter & Company (Ad)SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANADecember 3, 2024 | prnewswire.comSana Biotechnology announces Fast Track designation for SC291December 3, 2024 | markets.businessinsider.comSana Biotechnology Gets FDA Fast Track Designation for SC291 Cell TherapyDecember 2, 2024 | marketwatch.comSee More Sana Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sana Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sana Biotechnology and other key companies, straight to your email. Email Address About Sana BiotechnologySana Biotechnology (NASDAQ:SANA), a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.View Sana Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
